Related Experiment Video

Updated: Jan 13, 2026

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies
13:24

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

12.2K

Impact of next-generation sequencing on routine clinical practice and patient inclusion in molecularly targeted

Mathieu Faigner1, Lucie Karayan-Tapon2,3, Ulrich Cortes3

  • 1Medical Oncology Department, CHU de Poitiers, 86000, Poitiers, France.

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|October 29, 2025
PubMed
Abstract

Insights

Routine genomic profiling identified actionable mutations in many cancer patients, but trial enrollment remained low. Expanding panel size and molecular tumor board discussions improved detection and trial inclusion rates, highlighting a need for better physician awareness.

Area of Science:

  • Oncology
  • Genomics
  • Clinical Trials

Background:

  • High-throughput sequencing advances biomarker discovery for targeted cancer therapies.
  • Gene panels are crucial for identifying actionable genomic alterations for clinical use and trial eligibility.

Purpose of the Study:

  • To assess the proportion of cancer patients with targetable molecular alterations and their trial enrollment using a routine panel.
  • To compare these proportions with a larger panel and molecular tumor board (MTB) approach.

Main Methods:

  • Analysis of patient eligibility and trial inclusion among cancer patients undergoing routine next-generation sequencing (NGS) at Poitiers University Hospital.
  • Identification of clinical trials via French National Cancer Institute (INCa) and ClinicalTrials.gov.
  • Assessment of inclusion rates with the FoundationOne CDx® (FO) panel.

Main Results:

  • 835 targetable mutations identified in 1456 patients (KRAS, BRAF, PIK3CA most common).
  • Only 10.6% of eligible patients were enrolled in trials; reasons for non-inclusion were often undocumented.
  • FoundationOne CDx® (FO) analysis increased actionable alteration detection from 34.0% to 64.0% and trial inclusion from 12.0% to 16.0%.

Conclusions:

  • Despite a significant number of patients having actionable alterations, clinical trial enrollment was limited.
  • Enhanced physician awareness of clinical trials is essential for optimizing patient enrollment and access to targeted therapies.
Keywords:
Baskets trialsMolecular biologyNext generation sequencingTargeted therapyUmbrella trials

More Related Videos

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease09:34

Targeted Next-generation Sequencing and Bioinformatics Pipeline to Evaluate Genetic Determinants of Constitutional Disease

Published on: April 4, 2018

34.6K
Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors11:15

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors

Published on: September 20, 2016

24.9K

Related Concept Videos

Next-generation Sequencing03:00

Next-generation Sequencing

The first human genome sequencing project cost $2.7 billion and was declared complete in 2003, after 15 years of international cooperation and collaboration between several research teams and funding agencies. Today, with the advent of next-generation sequencing technologies, the cost and time of sequencing a human genome have dropped over 100 fold.
Next-Generation Sequencing Methods
Although all next-generation methods use different technologies, they all share a set of standard features....
97.7K
Clinical Trials: Overview01:11

Clinical Trials: Overview

Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.5K
Genomics02:02

Genomics

Genomics is the science of genomes: it is the study of all the genetic material of an organism. In humans, the genome consists of information carried in 23 pairs of chromosomes in the nucleus, as well as mitochondrial DNA. In genomics, both coding and non-coding DNA is sequenced and analyzed. Genomics allows a better understanding of all living things, their evolution, and their diversity. It has a myriad of uses: for example, to build phylogenetic trees, to improve productivity and...
39.6K
Sanger Sequencing01:57

Sanger Sequencing

DNA sequencing is a fundamental technique that is routinely used in the biological sciences. This method can be applied to a range of questions at different scales - from the sequencing of a cloned DNA fragment or the study of a mutation in a gene up to whole-genome sequencing. However, despite the widespread use of sequencing today, it was not until 1977 that Fredrick Sanger and his collaborators developed the chain-termination method to decode DNA sequences. It relies on the separation of a...
773.1K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.9K